ReviewCurrent opinion in endocrine and metabolic research2021
Emulating the gut-liver axis: Dissecting the microbiome's effect on drug metabolism using multiorgan-on-chip models.
Review in Current opinion in endocrine and metabolic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Inter-Organ Crosstalk in Neurodegenerative Disease.Life (Basel, Switzerland) · 2025Review
- The psychostimulant drug, fenethylline (captagon): Health risks, addiction and the global impact of illicit trade.Drug and alcohol dependence reports · 2025Review
- Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma.Frontiers in immunology · 2025Review
- Review
- Liver-on-chips for drug discovery and development.Materials today. Bio · 2024Review
- Buds and Bugs: A Fascinating Tale of Gut Microbiota and Cannabis in the Fight against Cancer.International journal of molecular sciences · 2024Review
- Integration of multiple flexible electrodes for real-time detection of barrier formation with spatial resolution in a gut-on-chip system.Microsystems & nanoengineering · 2024Article
- Short chain fatty acids: key regulators of the local and systemic immune response in inflammatory diseases and infections.Open biology · 2023Review
- Gut-on-a-chip models for dissecting the gut microbiology and physiology.APL bioengineering · 2023Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- Real-time monitoring of immediate drug response and adaptation upon repeated treatment in a microfluidic chip system.Archives of toxicology · 2022Article
- Gut-on-a-chip for disease models.Journal of tissue engineeringReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The homeostatic relationship between the gut, its microbiome, and the liver is crucial for the regulation of drug metabolism processes. Gut microbes are known to influence human health and disease by enhancing food metabolism and providing a first line of defense against pathogens. In addition to this, the gut microbiome also plays a key role in the processing of exogenous pharmaceutical compounds. Modeling the highly variable luminal gut environment and understanding how gut microbes can modulate drug availability or induce liver toxicity remains a challenge. However, microfluidics-based technologies such as organ-on-chips could overcome current challenges in drug toxicity assessment assays because these technologies are able to better recapitulate complex human responses. Efforts are being made to create
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.